Orbital Inflammatory Disease
Non-infectious orbital inflammation encompasses a spectrum of conditions — from idiopathic pseudotumor to systemic autoimmune diseases — each requiring a distinct diagnostic and treatment approach.
Idiopathic Orbital Inflammation (Orbital Pseudotumor)
Idiopathic orbital inflammation (IOI), historically called orbital pseudotumor, is the most common cause of painful orbital disease in adults. It is a diagnosis of exclusion — a non-granulomatous, non-specific inflammatory process with no identifiable local or systemic cause. The acute form presents dramatically with rapid-onset periorbital pain, swelling, proptosis, and restricted eye movement. Bilateral involvement or a chronic, sclerosing pattern should prompt thorough investigation for systemic disease.
Subtypes by Anatomic Location
Dacryoadenitis
Lacrimal gland inflammation — S-shaped ptosis, tender swelling under the outer brow. Most common subtype.
Myositis
One or more extraocular muscles inflamed and enlarged. Painful eye movement, often mimics thyroid eye disease but muscles include the tendon.
Anterior (scleritis/perineuritis)
Affects the anterior orbit, sclera, or optic nerve sheath. May mimic orbital cellulitis.
Apical
Inflammation at the orbital apex. High risk of optic nerve compression and vision loss; requires urgent treatment.
Diffuse
Involves multiple orbital structures simultaneously. Often more resistant to steroid therapy and carries higher risk of relapse.
The Steroid Test
A dramatic clinical response to oral corticosteroids within 24–72 hours is nearly pathognomonic for IOI. Failure to improve — or rapid relapse — mandates orbital biopsy to exclude lymphoma, IgG4-related disease, and other masquerades.
IgG4-Related Orbital Disease
IgG4-related disease (IgG4-RD) is a fibro-inflammatory condition characterized by tissue infiltration with IgG4-secreting plasma cells, storiform fibrosis, and — in some cases — obliterative phlebitis. In the orbit, it most commonly affects the lacrimal gland (producing a firm, painless enlargement) and the extraocular muscles. It was recognized as a distinct entity only in the 2000s and was previously misclassified as sclerosing pseudotumor, Mikulicz disease, or multifocal fibrosclerosis.
Clinical Features
- ·Bilateral, painless lacrimal gland enlargement (most common)
- ·Slowly progressive proptosis, often without pain
- ·Elevated serum IgG4 (>135 mg/dL) in ~60–70% of cases
- ·Associated systemic IgG4-RD (pancreatitis, aortitis, sialadenitis)
- ·High relapse rate after steroid taper
Diagnostic Criteria
- ·Tissue biopsy is required for definitive diagnosis
- ·Histology: IgG4+ plasma cells >10/high-power field with IgG4:IgG ratio >40%
- ·Storiform fibrosis on H&E staining
- ·Systemic work-up: CT chest/abdomen, pancreatic enzymes, rheumatology referral
- ·Elevated serum IgG4 supports but does not confirm diagnosis
Treatment: Glucocorticoids produce initial remission in most patients, but relapse on taper is common. Rituximab (anti-CD20 B-cell depletion) has become the preferred steroid-sparing agent and significantly reduces relapse rates compared to conventional immunosuppression.
Systemic Inflammatory Conditions Affecting the Orbit
Orbital Sarcoidosis
Sarcoidosis is a systemic granulomatous disease of unknown etiology that affects the orbit in approximately 25% of patients with ocular involvement. The lacrimal gland is most commonly affected, presenting with bilateral firm enlargement and a classic “panda sign” on gallium scan.
Key Features
- ·Non-caseating granulomas on biopsy — pathognomonic
- ·Elevated serum ACE and lysozyme (neither sensitive nor specific)
- ·Bilateral hilar adenopathy on CXR in ~90% of cases
- ·Uveitis, optic nerve, and retinal involvement also occur
Workup: CXR/CT chest, ACE, serum calcium, 24-hour urine calcium, pulmonology referral, and tissue biopsy. Conjunctival or lacrimal gland biopsy provides accessible tissue. Treatment: oral corticosteroids; methotrexate for steroid-sparing; infliximab for refractory cases.
Granulomatosis with Polyangiitis (GPA)
GPA (formerly Wegener’s granulomatosis) is a systemic necrotizing vasculitis affecting small and medium vessels. Orbital involvement occurs in 15–20% of patients, typically by direct extension of nasal or sinus disease, and may present with proptosis, scleritis, or dacryoadenitis.
Key Features
- ·c-ANCA (PR3-ANCA) positive in >90% of active systemic disease
- ·Upper airway: chronic sinusitis, nasal crusting, saddle-nose deformity
- ·Pulmonary nodules or cavitary lesions on CT chest
- ·Renal disease (crescentic glomerulonephritis) — life-threatening
When Is Orbital Biopsy Required?
Orbital biopsy is the definitive diagnostic tool when imaging and laboratory investigations are inconclusive, when clinical presentation is atypical, or when the diagnosis would alter management. For anterior lesions (lacrimal gland, anterior fat, accessible masses), the procedure is typically performed under local anesthesia in an outpatient or office-based setting through an anterior orbitotomy approach.
Indications for Biopsy
- ·No response to corticosteroids within 48–72 hours
- ·Rapid relapse after steroid taper
- ·Atypical imaging — irregular margins, bone erosion
- ·Bilateral or multifocal disease requiring systemic diagnosis
- ·Suspected IgG4-RD — histology required for diagnosis
- ·Concern for lymphoma or malignancy
- ·Chronic sclerosing pattern
- ·Child or immunocompromised patient — rhabdomyosarcoma must be excluded
The specimen is sent for histopathology, immunohistochemistry (IgG4, CD20, CD3, CD5 staining), and flow cytometry when lymphoma is a concern. Fresh tissue (not formalin-fixed) is required for flow cytometry — the specimen handling protocol must be confirmed with the pathology laboratory before the procedure.
Treatment Comparison
| Condition | First-Line | Second-Line | Refractory | Biopsy Role |
|---|---|---|---|---|
| IOI / Pseudotumor | Oral prednisone 1 mg/kg/day × 2–4 weeks then taper | Orbital radiation (20 Gy in 10 fractions) | Rituximab or methotrexate for steroid-dependent cases | If atypical features, no response to steroids within 48–72 h, or recurrence |
| IgG4-Related Orbital Disease | Oral glucocorticoids — usually prompt initial response | Rituximab (B-cell depletion) — preferred steroid-sparing agent | Azathioprine or mycophenolate mofetil | Required for definitive diagnosis: IgG4+ plasma cells > 10/HPF with storiform fibrosis |
| Sarcoidosis | Oral or periocular corticosteroids | Methotrexate — most widely used steroid-sparing agent | Infliximab for refractory cases | Tissue confirmation required; conjunctival or lacrimal gland biopsy often accessible |
| GPA (formerly Wegener's) | High-dose IV methylprednisolone + cyclophosphamide or rituximab | Rituximab now preferred over cyclophosphamide for induction | Azathioprine or methotrexate for maintenance |
Related Pages
Orbital Inflammation Care
Schedule an evaluation with Mark S. Brown, MD. Orbital inflammatory disease requires coordinated imaging, biopsy when needed, and medical management.